On September 6, 2023, Daniel Swisher, Jr., President and Chief Operating Officer of Jazz Pharmaceuticals plc announced the company of his intention to retire from the Company, effective March 31, 2024 (the Retirement Date). In connection therewith, Mr. Swisher will cease performing the duties and responsibilities of the Company?s President and Chief Operating Officer and will resign from any office or directorship at any affiliated entity of the Company, effective October 1, 2023. Mr. Swisher will continue to be employed by the Company as a non-executive employee through and until the Retirement Date or such earlier date as determined by the Company (such period, the Transition Period), during which time Mr. Swisher will assist in the transition of his responsibilities and duties.

The Company expects Mr. Swisher to continue his employment through the Transition Period to support a smooth transition. On September 11, 2023, the Board appointed Renée Galá as the Company?s President and Chief Operating Officer, effective as of October 1, 2023, to succeed Mr. Swisher as the Company?s President and Chief Operating Officer. In connection therewith, effective as of October 1, 2023, Ms. Galá will cease serving in the office of the Company?s Executive Vice President and will cease performing the duties and responsibilities of the Company?s Executive Vice President.

Ms. Galá, age 51, has served as the Company?s Executive Vice President and Chief Financial Officer since March 2020. From January to June 2019, Ms. Galá served as the Chief Financial Officer of GRAIL Inc. Prior to that, from December 2014 to January 2019, she served as Senior Vice President and Chief Financial Officer of Theravance Biopharma Inc. Ms. Galá joined Innoviva in 2006 and held various roles in the finance organization before leading the company?s spin-out transaction. Prior to that, Ms. Galá served in various roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and Company, from 2001 to 2006.

Before joining Eli Lilly, Ms. Galá spent seven years in the energy industry in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Galá serves on the board of directors of Gossamer Bio Inc., where she also chairs the audit committee. Ms. Galá previously served as a member of the board of Gyroscope Therapeutics (acquired by Novartis) and Corcept Therapeutics.

Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.